IBI sees annual sales of $1.6-2.4 billion for Teva migraine drug - Globes

Globes
IBI sees annual sales of $1.6-2.4 billion for Teva migraine drug
Globes
After Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) obtained the long-awaited marketing approval from the US Food and Drug Administration (FDA) for its Ajovy (formerly Fremanezumab) drug for treatment of migraines, IBI Investments ...y más »